India’s love for K-ice cream spurs Lotte to boost expansion
South Korean confectionery giant Lotte Wellfood Co. is targeting 15% sales growth in India this year, following the completion of a merger betw...
Celltrion secures $730 mn to buy biosimilar unit shares, pursue M&A
Celltrion Holdings Co. has secured 1 trillion won ($732 million) in fresh funding and plans to spend half of it this year to buy shares in its biosi...
Lotte Chemical, HD Hyundai seek to combine naphtha cracking facilities
Lotte Chemical Corp. and HD Hyundai Co. are in talks to consolidate their naphtha cracking operations in South Korea’s Daesan petrochemical co...
Celltrion shares rise after bonus issue announcement
Celltrion Inc., South Korea’s largest biosimilar developer, will issue bonus shares to bolster its stock performance, which has been in the do...
Korea’s top cinema chains seek merger to counter box office slump
South Korea’s two leading multiplex operators Lotte Culture Works Co. and Contentree JoongAng Corp. have tentatively agreed to merge in a bid ...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
StockX in merger talks with Naver’s online reseller Kream
StockX, the world’s most popular online resale marketplace, is in talks to merge with Kream, a resale unicorn under South Korea’s tech g...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
Celltrion to cancel $140 mn in treasury shares, stock up
South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of treasury shares to i...
Naver to name new CFO as incumbent financial manager's term nears end
South Korea’s tech giant Naver Corp. is expected to soon announce a new chief financial officer as its current CFO Kim Nam-sun, credited for t...
Hanwha Energy begins IPO process, key to 3rd-generation shift
Hanwha Energy Corp., wholly owned by Hanwha Group Chairman Kim Seung-youn’s three sons, has embarked on the process of going public – a ...
Samsung, Celltrion lead biosimilar market in Europe, US
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...
CHA Biotech seeks to resume healthcare unit IPO after affiliates’ merger
CHA Biotech Co., South Korea’s leading stem cell therapeutics developer, plans to resume an initial public offering of CHA Healthcare Co., a m...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
SK On to complete merger with SK Enterm on Feb. 1
Electric vehicle battery maker SK On Co. said on Friday it is set to complete a merger with crude oil storage tank operator SK Enterm Co. on Feb. 1 ...
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
Korean drugmakers control more than half of European biosimilar market
South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
Celltrion BioSolutions launched to venture into CDMO
Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDM...
Celltrion’s 4 new biosimilars win EU approval recommendation
Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...
Celltrion to allot cash, stock dividend at once
South Korea’s biosimilar maker Celltrion Inc. on Friday announced a plan to allot cash and stock dividends simultaneously. The company wi...
Doosan Robotics’ merger with Bobcat fails on share price plunge
Doosan Group on Tuesday canceled Doosan Bobcat Co.'s merger with Doosan Robotics Inc. again after President Yoo Suk Yeol’s failed martial law ...
NPS steps back from Doosan Robotics' Bobcat merger
The National Pension Service (NPS) appears to be stalling on a vote for Doosan Robotics Inc.'s merger with Doosan Bobcat Inc., with major proxy advi...
Celltrion gets approval of Omlyclo in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...
Celltrion to retire $400 mn treasury stock in January
South Korea’s biosimilar maker Celltrion Inc. on Wednesday announced a plan to retire about a quarter of its treasury stock worth 563 billion ...
Rebellions · Sapeon Korea merger, the first domestic AI chip unicorn
Rebellions Inc., a South Korean artificial intelligence chip design startup, officially merged with Sapeon Korea to form the first domestic AI chi...
Korean Air-Asiana merger to spur M&A among budget carriers
Korean Air Lines Co.'s anticipated acquisition of Asiana Airlines Inc. is expected to spur domestic budget carriers to seek mergers, with the two do...
